Want to see CNSY full AI Analyst Report?
Top Page
Cerenome
(NASDAQ:CNSY)
Select Model
Select Model
Rating:41Neutral
Price Target:
$2.50
▼(-18.83% Downside)
Action:Reiterated
Date:08/19/26
Overall score is driven primarily by weak financial performance—large ongoing losses and significant negative operating/free cash flow—despite a cleaner, low-debt balance sheet. Technicals add additional pressure because the stock trades below key moving averages with negative MACD, while valuation is constrained by negative earnings and no dividend yield data.
Positive Factors
Low Leverage
The very low debt burden provides a stronger balance-sheet foundation than in 2023–2024, when debt was higher and equity was negative. Minimal leverage reduces fixed financing pressure and preserves some flexibility to direct capital toward clinical development.
Negative Factors
Sustained Cash Burn
Persistent, sizable operating and free-cash-flow deficits show that the business does not currently fund its activities internally. Continued clinical development will therefore likely require ongoing financing, increasing dependence on capital markets and potentially dilutive funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
The very low debt burden provides a stronger balance-sheet foundation than in 2023–2024, when debt was higher and equity was negative. Minimal leverage reduces fixed financing pressure and preserves some flexibility to direct capital toward clinical development.
Read all positive factors
Cerenome (CNSY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$20.91M
Dividend YieldN/A
Average Volume (3M)75.09K
Price to Earnings (P/E)―
Beta (1Y)1.49
Revenue Growth-20.95%
EPS Growth91.97%
CountryUS
Employees28
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-1033.41
Shares Outstanding7,589,625
10 Day Avg. Volume52,382
30 Day Avg. Volume75,093
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.15
Price to Sales (P/S)2.42
P/FCF Ratio-0.60
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$50.00Price Target Upside1523.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.05
Revenue Forecast (FY)$5.88M
Cerenome Business Overview & Revenue Model
Company Description
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLipo...
How the Company Makes Money
Plus Therapeutics is a clinical-stage company and does not consistently generate product sales like a commercial pharmaceutical company. Its ability to make money is primarily tied to (1) external financing and (2) potential future monetization of...
Cerenome Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
46
Neutral
Cash Flow
21
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.20M | 5.21M | 5.82M | 4.91M | 224.00K | 0.00 |
| Gross Profit | 3.77M | 4.77M | 4.97M | -4.78M | -488.00K | -66.00K |
| EBITDA | -22.39M | -18.33M | -8.40M | -12.29M | -18.85M | -12.05M |
| Net Income | -26.09M | -22.39M | -12.98M | -13.32M | -20.27M | -13.40M |
Balance Sheet | ||||||
| Total Assets | 14.03M | 16.32M | 6.63M | 11.39M | 23.87M | 21.98M |
| Cash, Cash Equivalents and Short-Term Investments | 8.59M | 8.76M | 3.61M | 8.55M | 18.12M | 18.40M |
| Total Debt | 44.00K | 821.00K | 3.37M | 4.18M | 5.75M | 6.99M |
| Total Liabilities | 8.57M | 12.33M | 15.58M | 12.74M | 17.42M | 11.14M |
| Stockholders Equity | 5.46M | 4.00M | -8.95M | -1.35M | 6.45M | 10.84M |
Cash Flow | ||||||
| Free Cash Flow | -23.55M | -20.84M | -10.70M | -13.01M | -13.73M | -10.42M |
| Operating Cash Flow | -22.18M | -20.77M | -10.55M | -12.85M | -12.97M | -10.28M |
| Investing Cash Flow | -2.95M | -854.00K | -4.11M | -160.00K | -759.00K | -82.00K |
| Financing Cash Flow | 25.25M | 30.31M | 6.19M | 3.44M | 13.45M | 20.42M |
Cerenome Technical Analysis
Negative
3.08
Price Trends
3.63
Negative
4.70
Negative
7.06
Negative
Market Momentum
-0.26
Positive
34.75
Neutral
43.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNSY, the sentiment is Negative. The current price of 3.08 is below the 20-day moving average (MA) of 3.19, below the 50-day MA of 3.63, and below the 200-day MA of 7.06, indicating a bearish trend. The MACD of -0.26 indicates Positive momentum. The RSI at 34.75 is Neutral, neither overbought nor oversold. The STOCH value of 43.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CNSY.
Cerenome Risk Analysis
Cerenome disclosed 62 risk factors in its most recent earnings report. Cerenome reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cerenome Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $31.00M | -0.74 | -59.18% | ― | -100.00% | 41.21% | |
48 Neutral | $91.28M | -1.13 | -70.14% | ― | ― | 16.04% | |
45 Neutral | $40.60M | -0.08 | 77.63% | ― | 6.81% | 11.95% | |
44 Neutral | $25.48M | -0.68 | -145.40% | ― | -100.00% | 82.57% | |
41 Neutral | $20.91M | >-0.01 | -394.17% | ― | -20.95% | 91.97% | |
41 Neutral | $10.36M | -0.19 | -1539.97% | ― | ― | 80.28% |
* Healthcare Sector Average
CNSY
Cerenome
2.76
-9.19
-76.94%
KPTI
Karyopharm Therapeutics
1.79
-4.46
-71.36%
TVRD
Tvardi Therapeutics
1.91
-27.75
-93.56%
BRNS
Barinthus Biotherapeutics
0.76
-0.46
-37.53%
SNTI
Senti Biosciences
0.33
-0.99
-74.85%
ACRV
Acrivon Therapeutics, Inc.
2.13
0.34
18.99%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.